Welcome to our dedicated page for Lantheus Holdings news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holdings stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus Holdings (NASDAQ: LNTH) announced its acquisition of Cerveau Technologies for the clinical-stage PET imaging agent MK-6240, which targets Tau tangles in Alzheimer’s disease. This acquisition diversifies Lantheus' radiopharmaceutical pipeline, providing access to the most widely-used Tau PET agent. MK-6240 is currently involved in over 60 clinical trials globally and can enhance diagnosis and treatment for the estimated 6.5 million Americans with Alzheimer’s. The acquisition includes an upfront payment, potential milestone payments, and double-digit royalties on sales.
Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, President and CEO, will present at the J.P. Morgan 2023 Healthcare Conference on January 11, 2023, at 1:30 p.m. PST. The webcast of the presentation will be accessible via the Investors section of the company’s website, where it will also be replayable for at least 30 days. Lantheus is focused on diagnostics, radiotherapeutics, and AI solutions to enhance patient outcomes and has over 65 years of experience in the healthcare sector.
Lantheus Holdings (NASDAQ: LNTH) announced the successful closing of strategic collaboration agreements with POINT Biopharma Global, aimed at enhancing diagnostics and radiotherapeutics. The closing was subject to standard conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act. With over 65 years of experience, Lantheus continues to focus on improving patient outcomes through innovative solutions. The agreement is expected to strengthen Lantheus' position in the life-changing radiopharmaceutical sector.
Lantheus Holdings (NASDAQ: LNTH) announced a strategic collaboration with SonoThera to combine its microbubble technology with SonoThera's ultrasound-guided, nonviral gene therapy platform. This partnership aims to enhance the delivery of genetic therapies, potentially offering a safer and more effective alternative to traditional viral vectors. Lantheus' microbubbles have been widely used in cardiac imaging, with over 21 million studies performed since 2001. The collaboration seeks to improve gene therapy applications through novel delivery methods, marking an innovative step in genetic medicine.
Lantheus Holdings announced the pricing of $500 million in convertible senior notes due 2027, targeting qualified institutional buyers. The company expects to net approximately $485 million after expenses, with proceeds partly used for a $150 million stock repurchase program. The notes, with a 2.625% interest rate, can be converted to common stock at a rate of 12.5291 shares per $1,000. The initial conversion price is about $79.81, a 42.5% premium over the recent stock price. The offering is set to close on December 8, 2022.
Lantheus Holdings (NASDAQ: LNTH) announced an offering of $500 million in convertible senior notes due 2027, with an option for an additional $75 million. These senior unsecured notes will be guaranteed by Lantheus Medical Imaging, and maturity is set for December 15, 2027. Proceeds will fund stock repurchases and general corporate purposes. The board has authorized up to $150 million for repurchases, with $75 million allocated for buying shares from note purchasers. The offering is limited to qualified institutional buyers under Rule 144A.
Lantheus Holdings (NASDAQ: LNTH) has appointed Amanda Morgan as Senior Vice President, Commercial, effective November 29, 2022. Reporting to COO Paul Blanchfield, Morgan will oversee all commercial activities, including Sales, Marketing, and Market Access. With over 20 years in healthcare, she previously served as Chief Revenue and Customer Officer at Acadia Pharmaceuticals and held senior roles at Shire Plc. Her leadership is anticipated to enhance the company's commercial strategy and patient outcomes.
Lantheus Holdings (NASDAQ: LNTH) announced the approval of the Import Drug License for DEFINITY, a diagnostic ultrasound enhancing agent, by China's National Medical Products Administration. DEFINITY is indicated for patients with suboptimal echocardiograms, helping to identify the left ventricular endocardial border. The commercialization will be handled by CR Double-Crane in China. This move aims to address the growing incidence of cardiovascular disease in China, where 20% of adults are affected.
Lantheus Holdings (NASDAQ: LNTH) has entered into a strategic collaboration with POINT Biopharma Global (NASDAQ: PNT) for exclusive worldwide rights to two late-stage radiopharmaceuticals, PNT2002 and PNT2003. Lantheus will pay $260 million upfront, with potential milestone payments reaching approximately $1.8 billion. The collaboration aims to enhance Lantheus’ prostate cancer portfolio and drive long-term revenue growth. Both companies will fund and complete clinical trials, with Lantheus retaining commercialization rights post-FDA approval.
Lantheus Holdings (NASDAQ: LNTH) announced that CFO Bob Marshall will present at the Jefferies London Healthcare Conference on November 16, 2022, at 8:00 a.m. GMT (3 a.m. EST). The live webcast can be accessed on the company's website, with a replay available for 30 days post-presentation. Lantheus has over 65 years of experience in improving patient outcomes through diagnostics, radiotherapeutics, and AI solutions, aimed at helping clinicians Find, Fight, and Follow disease. The company is based in Massachusetts, with additional offices in New Jersey, Canada, and Sweden.